Roche begins new clinical trials of multiple sclerosis drugs – Clinical Trials Arena

Roche has launched a Phase III clinical trial programme of its experimental drug fenebrutinib for the treatment of patients with multiple sclerosis (MS).

The company also commenced a higher-dose Phase III programme for Ocrevus (ocrelizumab), along with a trial of the drug specifically to support African American, Hispanic, and Latin American MS patients.

Fenebrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor being developed for relapsing MS (RMS) and primary progressive MS (PPMS).

Click here to read full article https://www.clinicaltrialsarena.com/news/roche-multiple-sclerosis-drugs/

Font Resize